Uğur Şahin, BioNTech CEO (Photo by: Andreas Arnold/picture-alliance/dpa/AP Images)
BioNTech delves into ADCs with $170M upfront weeks after Pfizer lines up Seagen
As its Covid vaccine partner Pfizer goes all in on the hot field of antibody-drug conjugates, BioNTech will enter the space as well in a $170 million upfront, $1.5 billion biobuck pact with a Shanghai biotech.
The German biotech will pair up with Duality Biologics to make two ADCs globally, save for Mainland China, Hong Kong and Macau. BioNTech, which has been lining up a series of deals to follow up on its breakout Covid vaccine with Pfizer, will use the deal to go after solid tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
